NEW YORK (GenomeWeb News) - Eli Lilly & Co. said today that it will provide free access to its drug discovery technology to potential collaborators who want to evaluate the therapeutic potential of their compounds.

Under the new program, called the Phenotypic Drug Discovery Initiative, or PD2, Lilly said it will provide free, confidential access to its drug discovery assays via a secure web portal in a move intended to provide "a more convenient point of entry for global external researchers into Lilly's drug discovery and development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.